title: Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
abstract: BACKGROUND
  Gait impairment is a common presenting symptom in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). However, gait parameters have not previously been evaluated in detail as potential independent outcome measures.
  
  
  METHODS
  We prospectively measured changes in spatiotemporal gait parameters of 20 patients with CIDP at baseline and following treatment with intravenous immunoglobulin (IVIG), using GAITRite® a computerized walkway system with embedded sensors.
  
  
  RESULTS
  Overall, study patients showed significant improvements in gait velocity, cadence, stride length, double support time, stance phase, and swing phase following IVIG treatment. Mean changes in velocity, stance phase, and swing phase, exhibited the greatest statistical significance among the subgroup that exhibited clinically meaningful improvement in Inflammatory Neuropathy Cause and Treatment disability score, Medical Research Council sum score, and grip strength.
  
  
  CONCLUSIONS
  Assessment of gait parameters, in particular velocity, step phase and swing phase, is a potentially sensitive outcome measure for evaluating treatment response in CIDP. Muscle Nerve 56: 732-736, 2017.
authors.affiliation: Peripheral Neuropathy Center, Weill Cornell Medical College, 1305 York Avenue, 2nd Floor, New York, New York, 10021, USA.
authors.forename: Mary L
authors.initials: ML
authors.lastname: Vo
authors.affiliation: Peripheral Neuropathy Center, Weill Cornell Medical College, 1305 York Avenue, 2nd Floor, New York, New York, 10021, USA.
authors.forename: Russell L
authors.initials: RL
authors.lastname: Chin
authors.affiliation: Department of Neurology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York, USA.
authors.forename: Caroline
authors.initials: C
authors.lastname: Miranda
authors.affiliation: Peripheral Neuropathy Center, Weill Cornell Medical College, 1305 York Avenue, 2nd Floor, New York, New York, 10021, USA.
authors.forename: Norman
authors.initials: N
authors.lastname: Latov
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D005260:Female; D005684:Gait / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D013037:Spatial Behavior / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous
keywords: CIDP; chronic inflammatory demyelinating polyneuropathy; gait analysis; intravenous immunoglobulin; outcome measures; spatiotemporal gait parameters